Continuing increased risk of oral/esophageal cancer after allogeneic hematopoietic stem cell transplantation in adults in association with chronic graft-versus-host disease

Annals of Oncology

Volumn 25, Issue 2, 2014, Pages 435-441

  Atsuta, Y ^a   Suzuki, R ^a   Yamashita, T ^b   Fukuda, T ^b   Miyamura, K ^c   Taniguchi, S ^d   Iida, H ^e   Uchida, T ^f   Ikegame, K ^g   Takahashi, S ^h   Kato, K ^c   Kawa, K ⁱ   Nagamura Inoue, T ^h   Morishima, Y ^j   Sakamaki, H ^k   Kodera, Y ^l  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL   (Japan)

^c JAPANESE RED CROSS NAGOYA FIRST HOSPITAL   (Japan)

^d TORANOMON HOSPITAL   (Japan)

^e Meitetsu Hospital   (Japan)

^f NAGOYA DAINI RED CROSS HOSPITAL   (Japan)

^g HYOGO COLLEGE OF MEDICINE   (Japan)

^h UNIVERSITY OF TOKYO   (Japan)

ⁱ RESEARCH INSTITUTE FOR MATERNAL AND CHILD HEALTH   (Japan)

^j AICHI CANCER CENTER HOSPITAL   (Japan)

^k TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

^l AICHI MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

more..

Author keywords

Hematopoietic stem cell transplantation; Late effect; Secondary solid cancers

Indexed keywords

ADOLESCENT; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BRAIN CANCER; CANCER INCIDENCE; CANCER RISK; CHRONIC GRAFT VERSUS HOST DISEASE; COLON CANCER; CONTROLLED STUDY; ESOPHAGUS CANCER; FEMALE; HUMAN; JAPAN; MAJOR CLINICAL STUDY; MALE; MOUTH CANCER; PRIORITY JOURNAL; RISK FACTOR; SKIN CANCER;

EID: 84893372474     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt558     Document Type: Article

References (23)

1. Copelan EA. Hematopoietic stem-cell transplantation. N Engl J Med 2006; 354: 1813-1826.
2. Gratwohl A, Baldomero H, Aljurf M et al. Hematopoietic stem cell transplantation: a global perspective. JAMA 2010; 303: 1617-1624.
3. Yoshimi A, Suzuki R, Atsuta Y et al. Hematopoietic SCT activity in Asia: a report from the Asia-Pacific Blood and Marrow Transplantation Group. Bone Marrow Transplant 2010; 45: 1682-1691.
4. Pasquini MC, Wang Z, Horowitz MM et al. 2010 report from the Center for International Blood and Marrow Transplant Research (CIBMTR): current uses and outcomes of hematopoietic cell transplants for blood and bone marrow disorders. Clin Transpl 2010; 87-105.
5. Passweg JR, Baldomero H, Gratwohl A et al. The EBMT activity survey: 1990-2010. Bone Marrow Transplant 2012; 47: 906-923.
6. Ahmed SO, Ghavamzadeh A, Zaidi SZ et al. Trends of hematopoietic stem cell transplantation in the Eastern Mediterranean region, 1984-2007. Biol Blood Marrow Transplant 2011; 17: 1352-1361.
7. Bhatia S, Ramsay NK, Steinbuch M et al. Malignant neoplasms following bone marrow transplantation. Blood 1996; 87: 3633-3639.
8. Curtis RE, Rowlings PA, Deeg HJ et al. Solid cancers after bone marrow transplantation. N Engl J Med 1997; 336: 897-904.
9. Kolb HJ, Socie G, Duell T et al. Malignant neoplasms in long-term survivors of bone marrow transplantation. Late Effects Working Party of the European Cooperative Group for Blood and Marrow Transplantation and the European Late Effect Project Group. Ann Intern Med 1999; 131: 738-744.
10. Bhatia S, Louie AD, Bhatia R et al. Solid cancers after bone marrow transplantation. J Clin Oncol 2001; 19: 464-471.
11. Shimada K, Yokozawa T, Atsuta Y et al. Solid tumors after hematopoietic stem cell transplantation in Japan: incidence, risk factors and prognosis. Bone Marrow Transplant 2005; 36: 115-121.
12. Rizzo JD, Curtis RE, Socie G et al. Solid cancers after allogeneic hematopoietic cell transplantation. Blood 2009; 113: 1175-1183.
13. Majhail NS, Brazauskas R, Rizzo JD et al. Secondary solid cancers after allogeneic hematopoietic cell transplantation using busulfan-cyclophosphamide conditioning. Blood 2011; 117: 316-322.
14. Yokota A, Ozawa S, Masanori T et al. Secondary solid tumors after allogeneic hematopoietic SCT in Japan. Bone Marrow Transplant 2012; 47: 95-100.
15. Curtis RE, Metayer C, Rizzo JD et al. Impact of chronic GVHD therapy on the development of squamous-cell cancers after hematopoietic stem-cell transplantation: an international case-control study. Blood 2005; 105: 3802-3811.
16. Leisenring W, Friedman DL, Flowers ME et al. Nonmelanoma skin and mucosal cancers after hematopoietic cell transplantation. J Clin Oncol 2006; 24: 1119-1126.
17. Friedman DL, Rovo A, Leisenring W et al. Increased risk of breast cancer among survivors of allogeneic hematopoietic cell transplantation: a report from the FHCRC and the EBMT-Late Effect Working Party. Blood 2008; 111: 939-944.
18. Atsuta Y, Suzuki R, Yoshimi A et al. Unification of hematopoietic stem cell transplantation registries in Japan and establishment of the TRUMP System. Int J Hematol 2007; 86: 269-274.
19. Gooley TA, Leisenring W, Crowley J et al. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999; 18: 695-706.
20. Cox DR. Regression model and life tables. J R Stat Soc B 1972; 34: 187-200.
21. Majhail NS, Rizzo JD, Lee SJ et al. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation. Bone Marrow Transplant 2012; 47: 337-341.
22. Majhail NS, Rizzo JD, Lee SJ et al. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation. Biol Blood Marrow Transplant 2012; 18: 348-371.
23. Baker KS, DeFor TE, Burns LJ et al. New malignancies after blood or marrow stem-cell transplantation in children and adults: incidence and risk factors. J Clin Oncol 2003; 21: 1352-1358.